COVID-19 vaccines were developed during one of the most urgent public health emergencies in modern history. They have been administered to billions of people worldwide and have helped reduce severe illness, hospitalisation and death from COVID-19.
At the same time, no medical intervention is completely without risk. While most people experienced no side effects or only short-lived reactions, a small number developed more serious adverse events. Some of these were identified quickly, while others only became apparent after millions of people had been vaccinated.
This raises an important question: how do we know when a vaccine side effect is real, and what happens once it is reported?
Understanding how vaccine safety is monitored helps explain why medical recommendations sometimes change, why rare risks can take time to identify, and why transparency is essential for maintaining public confidence
COVID-19 vaccines continue to be monitored long after approval. In the UK, suspected side effects are reported through the Yellow Card Scheme, alongside other national and international safety systems. A single report does not prove that a vaccine caused a medical problem, but repeated reports can identify patterns that prompt further investigation. This ongoing surveillance has led to the recognition of several rare adverse events and continues to improve vaccine safety.
Key Insights
- Vaccine safety monitoring continues long after approval.
- Rare side effects may only become apparent after millions of doses have been given.
- The Yellow Card Scheme identifies possible safety signals but does not establish causation.
- Medical recommendations are updated as new evidence emerges.
- Open discussion of both benefits and risks is essential for public trust.
Why Vaccine Safety Doesn’t End After Approval
Before any vaccine is approved, it undergoes laboratory testing and several phases of clinical trials designed to assess both effectiveness and safety.
However, even the largest clinical trials have limits.
If a side effect occurs once in every 100,000 or one million people, it may not appear until the vaccine is used by much larger populations. This is why approval is not the end of safety testing. It marks the beginning of continuous real-world monitoring involving millions of people.
In many ways, the largest safety study begins only after a vaccine enters routine clinical use.
How Are Vaccine Side Effects Monitored?
In the United Kingdom, suspected side effects are monitored through the Yellow Card Scheme, operated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Anyone can submit a report, including patients, carers and healthcare professionals.
The purpose of the system is not to confirm that a vaccine caused a particular illness. Instead, it acts as an early warning system.
When similar reports begin appearing more often than expected, researchers investigate whether they represent a genuine safety signal or whether the association may be coincidental.
This process is known as pharmacovigilance—the ongoing monitoring of medicines and vaccines after they have been approved.
Why Doesn’t One Report Prove Causation?
One of the biggest misunderstandings about vaccine safety monitoring is the belief that a reported side effect automatically means the vaccine caused it.
In reality, people continue to develop illnesses every day, whether they have recently received a vaccine or not.
The challenge for researchers is determining whether a condition is occurring more frequently than would normally be expected in the population.
To answer this, scientists combine information from many different sources, including Yellow Card reports, electronic health records, epidemiological studies, international databases and laboratory research. They also consider whether there is a biologically plausible explanation for the observed pattern.
Only when multiple lines of evidence point in the same direction can a causal relationship be established with confidence.
What Did We Learn During the COVID-19 Vaccination Programme?
The COVID-19 vaccination programme became one of the largest medicine safety monitoring programmes ever undertaken.
As hundreds of millions of doses were administered worldwide, surveillance systems identified several rare but important adverse events that had not been detected during clinical trials because of their rarity.
One example was thrombosis with thrombocytopenia syndrome (TTS) associated with the Oxford-AstraZeneca vaccine. Another was myocarditis and pericarditis, which were identified as rare adverse events following some mRNA vaccines, particularly in younger males.
As evidence accumulated, vaccination guidance was updated in several countries to reduce these risks while continuing to protect people from severe COVID-19.
This illustrates one of the strengths of ongoing safety monitoring: recommendations are refined as new evidence becomes available.
The Human Experience Behind the Data
For most people, vaccination is straightforward and uneventful.
For others, the experience is very different.
A small number of individuals develop symptoms that are severe, prolonged or difficult to explain. Some receive a recognised diagnosis linked to vaccination, while others continue living with symptoms that remain uncertain despite extensive medical investigations.
For these individuals, submitting a Yellow Card report may be one of the few ways to formally document what has happened.
Although these reports contribute valuable information to safety monitoring, they do not automatically provide a diagnosis, treatment or ongoing clinical support. This can leave some people feeling unheard at a time when they are looking for answers.
Listening carefully to these experiences is an important part of improving both research and patient care.
Why Transparency Matters
Public confidence depends on honesty.
People are more likely to trust public health systems when benefits, risks and uncertainties are discussed openly rather than selectively.
Recognising that rare adverse events exist does not undermine vaccination programmes. On the contrary, acknowledging them and investigating them carefully demonstrates that safety systems are working as intended.
Medicine advances by continually questioning, measuring and refining its understanding as new evidence emerges.
Can Vaccine Safety Monitoring Improve?
Safety monitoring systems continue to evolve.
Increasing awareness of reporting systems may improve the detection of rare adverse events.
Providing clearer information about what happens after a report is submitted could help reduce uncertainty for patients.
Improving access to specialist assessment and follow-up for people experiencing persistent symptoms would also strengthen confidence in the healthcare system.
Finally, continued long-term research remains essential to better understand uncommon adverse events, improve treatment pathways and guide future vaccination programmes.
A Different Way to Think About Vaccine Safety
Many people think of vaccine approval as the final step.
In reality, it is the point where the most extensive phase of safety monitoring begins.
Clinical trials answer many important questions before approval. Real-world surveillance answers new questions that only become possible once millions of people have received the vaccine.
Rather than seeing safety monitoring as a sign that something has gone wrong, it should be viewed as an essential part of responsible medical practice—one that continues to improve our understanding over time.
Frequently Asked Questions
What is the Yellow Card Scheme?
The Yellow Card Scheme is the UK’s official system for reporting suspected side effects associated with medicines and vaccines. It helps the MHRA identify potential safety signals that may require further investigation.
Does reporting a side effect prove that the vaccine caused it?
No. A report records a suspected association. Researchers examine many reports together with clinical studies and other scientific evidence before determining whether there is a causal relationship.
Why are some vaccine side effects only discovered after approval?
Very rare side effects may not occur often enough to be detected during clinical trials. They may only become apparent after millions of people have received the vaccine, which is why ongoing safety monitoring is essential.
Can patients report suspected vaccine side effects?
Yes. Patients, carers and healthcare professionals can all submit reports through the Yellow Card Scheme if they suspect a medicine or vaccine may have caused an adverse effect.
Are serious vaccine side effects common?
No. Most vaccine side effects are mild and temporary. Serious adverse events are uncommon, but they can occur and are continuously monitored so that guidance can be updated if new risks are identified.
Conclusion
COVID-19 vaccines have had a major impact on reducing severe disease during the pandemic, but like all medicines, they are not entirely without risk.
The COVID-19 vaccination programme also demonstrated the importance of robust safety monitoring. Rare adverse events were identified, investigated and, where necessary, led to changes in public health recommendations.
Understanding how systems such as the Yellow Card Scheme work helps explain why medicine continues to learn long after a treatment is approved.
Ultimately, maintaining trust depends not on claiming that medicines are risk free, but on investigating concerns carefully, communicating evidence honestly and ensuring that people affected by rare adverse events are recognised, supported and included in ongoing research.Acknowledging rare adverse events should never be seen as being “anti-vaccine”. It is part of good medicine. Every medical intervention has potential benefits and potential risks, and understanding both is essential for informed decision-making and maintaining public trust.
Suggested Reading
- Why Are My Long COVID Tests Normal?
- Can Vaccinated People Still Get Long COVID?
- Why Medical Advice Changes Over Time coming soon
References
- Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card Scheme.
- MHRA. Coronavirus (COVID-19) vaccine safety reports.
- World Health Organization (WHO). COVID-19 vaccines: Safety surveillance manual.
- European Medicines Agency (EMA). Safety monitoring of COVID-19 vaccines.
- Centers for Disease Control and Prevention (CDC). Understanding How Vaccines Work.
Last Update July 2026